CYBB and Alzheimer disease: In an AD-like model of dementia by the intracerebroventricular (ICV) administration of streptozotocin (STZ), advanced glycation end-products (AGEs), derived from methylglyoxal, activate receptors for AGEs (RAGE) that in turn activate NOX2, that ultimately results in being persistently activated [77].